Pavani Guntur, MD
Neurology · Los Angeles, CANPI 1306167291
Payments from drug & device makers
Across 47 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$516
- Teva Pharmaceuticals USA, Inc.$235
- Catalyst Pharmaceuticals, Inc.$178
- Biogen$80
- UCB, Inc.$79
- Acorda Therapeutics, Inc$24
- plus $42 from 3 others
What the payments were for
- Speaking & faculty fees$242%
- Food & beverage$1,13198%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $516 |
| Teva Pharmaceuticals USA, Inc. | 4 | $235 |
| Catalyst Pharmaceuticals, Inc. | 1 | $178 |
| Biogen | 7 | $80 |
| UCB, Inc. | 1 | $79 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Amgen | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,155 in reported general payments places this provider in the 45th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 22 | $29,721 |
| RytaryCarbidopa/Levodopa | 18 | $27,027 |
| KeppraLevetiracetam | 12 | $26,400 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $25,220 |
| Emgality PenGalcanezumab-Gnlm | 15 | $10,605 |
| Memantine Hcl | 48 | $3,145 |
| Gabapentin | 116 | $2,559 |
| Entacapone | 13 | $2,242 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 55 | $1,566 |
| Duloxetine Hcl | 44 | $1,018 |
| Pregabalin | 43 | $731 |
| Levetiracetam | 22 | $706 |
| Nortriptyline Hcl | 21 | $658 |
| Donepezil Hcl | 68 | $635 |
| Lamotrigine | 16 | $518 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.